Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07636226CT.gov QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07632209CT.gov Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment | — | Not Yet Recruiting | — | — | — |
NCT07538271CT.gov A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07538258CT.gov Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07501169CT.gov Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | — | Not Yet Recruiting | — | — | — |
NCT07388875CT.gov Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC | — | Not Yet Recruiting | — | — | — |
NCT07358676CT.gov A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07376499CT.gov Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | — | Not Yet Recruiting | — | — | — |
NCT07172412CT.gov Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07022301CT.gov Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy | — | Not Yet Recruiting | — | — | — |
Show 33 more trialsShow fewer
NCT06978153CT.gov This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06951841CT.gov Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | — | Not Yet Recruiting | — | — | — |
NCT06931145CT.gov Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06897579CT.gov Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT06469879CT.gov A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients | — | Not Yet Recruiting | — | — | — |
NCT06441344CT.gov Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell | — | Not Yet Recruiting | — | — | — |
NCT06258642CT.gov Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | — | Recruiting | — | — | — |
NCT05896059CT.gov A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | — | Unknown | — | — | — |
NCT05027100CT.gov Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | — | Unknown | — | — | — |
NCT04985851CT.gov To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | — | Unknown | — | — | — |
NCT04967625CT.gov A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC | — | Unknown | — | — | — |
NCT04933175CT.gov Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer | — | Unknown | — | — | — |
NCT04660097CT.gov Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | — | Completed | — | — | — |
NCT04882033CT.gov Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05001971CT.gov Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy | — | Completed | — | — | — |
NCT04620837CT.gov Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | — | Unknown | — | — | — |
NCT04363255CT.gov First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | — | Unknown | — | — | — |
NCT04314297CT.gov Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | — | Unknown | — | — | — |
NCT04234607CT.gov A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) | — | Unknown | — | — | — |
NCT04757779CT.gov A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | — | Unknown | — | — | — |
NCT04073550CT.gov Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04165330CT.gov Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04192682CT.gov Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04684017CT.gov Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03841136CT.gov Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer | — | Unknown | — | — | — |
NCT03890055CT.gov Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride | — | Unknown | — | — | — |
NCT03700359CT.gov A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | — | Unknown | — | — | — |
NCT03823118CT.gov S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer | — | Completed | — | — | — |
NCT03780283CT.gov Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | — | Unknown | — | — | — |
NCT03781869CT.gov Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03732846CT.gov Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04731909CT.gov Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03059797CT.gov Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catequentinib (this asset) | Sun Yat-sen University | Approved | BB · 65 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Catequentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P3 | BB · 70 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BB · 66 |
| Kidney Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catequentinib in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catequentinib-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →